SYRE · NASDAQ · STOCK
Spyre Therapeutics (SYRE) Stock Analysis
$91.24
52W $14.51 – $110.17
62/100
$7.90B
-46.6
3.00
Is SYRE Bullish or Bearish?
Bullish.
Innellis AI committee rates Spyre Therapeutics, Inc. (SYRE) Buy with a composite score of 62/100
, based on 6 analysts with 50% agreement.
Last updated September 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.54 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.46 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.30 across 10 articles, 14d) — News
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 35.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 17, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 24%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -24.3% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 35.8% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
67
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.30 across 10 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Investment Thesis Evolution
Committee score moved marginally from 62.5 to 62.5.
Comparing 2026-09-16 to 2026-09-17 (1 day apart).
Technical Analysis
RSI (14)
46.2
Neutral
MACD Histogram
-0.266
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.38
Inside Bands
Price vs Moving Averages
EMA 9
$90.53
Above
EMA 21
$93.43
Below
EMA 50
$93.77
Below
EMA 200
$69.74
Above
Fundamental Analysis
Valuation
72
Growth
85
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-46.6×
P/B Ratio
7.00×
PEG Ratio
0.91
Dividend Yield
0.00%
52W High
$110.17
52W Low
$14.51
Quality & Growth
ROE
-2170.0%
ROA
-1995.5%
Gross Margin
0.0%
Operating Margin
-22249.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -46.6 (inexpensive relative to a 15-40x range); Price-to-book of 7.0x; PEG ratio of 0.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -21.7%; Return on assets of -20.0%; Net margin of -197.7%; Gross margin of 0.0%; Current ratio of 18.53 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.47); Most recent quarter beat estimates by 53.5%; EPS growth accelerating (-5.7% -> +51.4% QoQ); Analyst estimates rising over recent quarters
Get the Full SYRE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →